REGISTERED PLAN PRIVATE INVESTMENTS INC.

Registered Plan Private Investments Inc.

LXGTF

CA5290204067

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 01:47:28 2024-03-28 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2023	Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Lexington Biosciences, Inc. Announces the Resignation of Eric Willis as its CEO & Director

February 12, 2020 at 09:13 pm EST

Lexington Biosciences, Inc. announced the resignation of Eric Willis as its CEO & Director.

Latest news about Registered Plan Private Investments Inc.

Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-04	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt	23-05-01	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-29	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-02	CI
Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt	22-05-01	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-28	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-31	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-29	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-31	CI
Lexington Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-01	CI
Lexington Biosciences, Inc. Approves the Election of Tamara Manuel as Director	20-04-27	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-21	CI
Lexington Biosciences, Inc. Announces Executive Changes	20-04-16	CI
Lexington Biosciences, Inc. announced that it expects to receive CAD 0.5 million in funding	20-02-19	CI
Lexington Biosciences Updates on License Termination	20-02-12	CI
Lexington Biosciences, Inc. Announces the Resignation of Eric Willis as its CEO & Director	20-02-12	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-28	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-27	CI

Chart Registered Plan Private Investments Inc.

Duration

Period

Chart Registered Plan Private Investments Inc.

More charts

Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a personâs vascular endothelium - the vital innermost lining of a personâs cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a personâs cardiovascular health.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
REGISTERED PLAN PRIVATE INVESTMENTS INC.	-.--%	27
ABBOTT LABORATORIES	-2.54%	186B
MEDTRONIC PLC	-1.85%	107B
BECTON, DICKINSON AND COMPANY	-4.26%	67.44B
DEXCOM, INC.	+1.39%	50.03B
CENCORA, INC.	+16.82%	47.81B
HOYA CORPORATION	+4.79%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	25.82B
ZIMMER BIOMET HOLDINGS, INC.	+0.01%	25.01B